Current status of veterinary vaccines

Clinical Microbiology Reviews

Volumn 20, Issue 3, 2007, Pages 489-510

  Meeusen, Els N T ^a   Walker, John ^b   Peters, Andrew ^c   Pastoret, Paul Pierre ^d   Jungersen, Gregers ^e  

^a MONASH UNIVERSITY   (Australia)

^b PFIZER INC   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Centre collaborateur de l'Organisation mondiale de la santé animale   (France)

^e TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADVENT; ANDROVAX; APEX IHN; AQUAVAC ERM; AQUAVAC FURUVAC; AQUAVAC VIBRIO; ART VAX; AVIAN INFLUENZA VACCINE; BACTERIAL VACCINE; BAYOVAC CSF E2; BOVILIS; BOVILIS IBR MARKER; CANCER VACCINE; COCCIVAC; COXABIC; DNA VACCINE; ENTERISOL ILEITIS; EPM VACCINE; EQUILIS STREPE; EQUITY; EURIFEL FELV; FECUNDIN; GIARDIAVAX; GONACON; IMMUCOX; IMPROVAC; INFLUENZA VACCINE; INOVOCOX; KENNEL COUGH VACCINE; LEISHMUNE; LIVACOX; LIVE VACCINE; MEGAN VAC1; NAKED DNA; NEOGUARD; NOBILIS COX ATM; OVASTIM; OVILIS ENZOVAX; OVILIS TOXOVAX; PARACOX; PERIOVAC; PIRODOG; PLEUROSTAR APP; PORCILIS; PORCILIS APP; PORCILIS PESTI; POULVAC FLUFEND; PREVENILE; PROTEQ FLU; PROTOZOAL VACCINE; PUREVAX; PUREVAXFERRET DISTEMPER; RABIES VACCINE; RB 51; RECOMBITEK; RECOMBITEK CANINE PARVO; RECOMBITEK CORONA MLV; RECOMBITEK RDISTEMPER; RECOMBITEKEQUINE WNV; RICKETTSIA VACCINE; SPAYVAC; SPERM ANTIGEN; STREPTOMYCIN; SUVAXYN; SUVAXYN AUJESZKY; TROVAC AI H5; UNCLASSIFIED DRUG; VACCINE; VAXSAFE MG; VAXSAFE MS; VAXSTRATE; VAXXITEK; VECTORMUNE FP ND; VIRUS VECTOR; WEST NILE INNOVATOR DNA;

AEROMONAS SALMONICIDA; ANAPLASMA CENTRALE; ANAPLASMA MARGINALE; AVIAN LYMPHOMATOSIS HERPETOVIRUS; BORDETELLA AVIUM; BRUCELLA ABORTUS; BRUCELLA SUIS; CAMPYLOBACTER JEJUNI; CANARYPOX VIRUS; CHLAMYDOPHILA PSITTACI; DRUG EFFICACY; EUROPE; FASCIOLA GIGANTICA; FASCIOLA HEPATICA; FERTILITY; FLAVIVIRUS; GENE DELETION; GENETIC ENGINEERING; INFECTIOUS BURSAL DISEASE VIRUS; INFLUENZA VIRUS A H3N8; LEISHMANIA CHAGASI; LEISHMANIA DONOVANI; LISTONELLA ANGUILLARUM; MYCOPLASMA GALLISEPTICUM; MYCOPLASMA SYNOVIAE; NETHERLANDS; NONHUMAN; REVIEW; SALMONELLA ENTERICA; SALMONELLA GALLINARUM; SALMONELLA TYPHIMURIUM; SYSTEMATIC REVIEW; UNITED STATES; VACCINATION; VIRUS GENE; VIRUS INFECTIVITY; WEST NILE FLAVIVIRUS; WILDLIFE; YELLOW FEVER FLAVIVIRUS; YERSINIA RUCKERI;

ALLERGENS; ANIMAL DISEASES; ANIMALS; ANIMALS, DOMESTIC; BACTERIAL VACCINES; CANCER VACCINES; COMMUNICABLE DISEASE CONTROL; FERTILITY; HYPERSENSITIVITY; NEOPLASMS; PROTOZOAN VACCINES; REPRODUCTION; VACCINATION; VACCINES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 34547471467     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.00005-07     Document Type: Review

References (198)

1. Alexander, A. N., M. K. Huelsmeyer, A. Mitzey, R. R. Dubielzig, I. D. Kurzman, E. G. Macewen, and D. M. Vail. 2006. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol. Immunother. 55:433-442.
2. Allan, G. M., F. McNeilly, J. Ellis, S. Krakowka, A. Botner, K. McCullough, H. Nauwynck, S. Kennedy, B. Meehan, and C. Charreyre. 2004. PMWS: experimental model and co-infections. Vet. Microbiol. 98:165-168.
3. Ashford, D. A., J. di Pietra, J. Lingappa, C. Woods, H. Noll, B. Neville, R. Weyant, S. L. Bragg, R. A. Spiegel, J. Tappero, and B. A. Perkins. 2004. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 22:3435-3439.
4. Azad, N., and Y. Rojanasakul. 2006. Vaccine delivery - current trends and future. Curr. Drug Deliv. 3:137-146.
5. Babu, U., R. A. Dalloul, M. Okamura, H. S. Lillehoj, H. Xie, R. B. Raybourne, D. Gaines, and R. A. Heckert. 2004. Salmonella enteritidis clearance and immune responses in chickens following Salmonella vaccination and challenge. Vet. Immunol. Immunopathol. 101:251-257.
6. Bain, R. K. 1999. Irradiated vaccines for helminth control in livestock. Int. J. Parasitol. 29:185-191.
7. Bain, R. K., and G. M. Urquhart. 1988. Parenteral vaccination of calves against the cattle lungworm Dictyocaulus viviparus. Res. Vet. Sci. 45:270-271.
8. Balamurugan, V., R. M. Kumar, and V. V. Suryanarayana. 2004. Past and present vaccine development strategics for the control of foot-and-mouth disease. Acta Virol. 48:201-214.
9. Balic, A., V. M. Bowles, and E. N. Meeusen. 2000. The immunobiology of gastrointestinal nematode infections in ruminants. Adv. Parasitol. 45:181-241.
10. Barbour, E. K., S. K. Hamadeh, and A. Eidt. 2000. Infection and immunity in broiler chicken breeders vaccinated with a temperature-sensitive mutant of Mycoplasma gallisepticum and impact on performance of offspring. Poult. Sci. 79:1730-1735.
11. Baron, M. D., A. C. Banyard, S. Parida, and T. Barrett. 2005. The Plowright vaccine strain of rinderpest virus has attenuating mutations in most genes. J. Gen. Virol. 86:1093-1101.
12. Barrett, T., P.-P. Pastoret, and W. Taylor. 2006. Rinderpest and peste des petits ruminants, virus plagues of large and small ruminants. Elsevier, London, United Kingdom.
13. Beer, M., I. Reimann, B. Hoffmann, and K. Depner. 4 January 2007, posting date. Novel marker vaccines against classical swine fever. Vaccine doi: 10.1016/j.vaccinc.2006.12.036.
14. Belknap, E. B., L. M. Walters, C. Kelling, V. K. Ayers, J. Norris, J. McMillen, C. Hayhow, M. Cochran, D. N. Reddy, J. Wright, and J. K. Collins. 1999. Immunogenicity and protective efficacy of a gE, gG and US2 gene-deleted bovine herpesvirus-1 (BITV-1) vaccine. Vaccine 17:2297-2305.
15. Belli, S. I., M. Lee, P. Thebo, M. G. Wallach, B. Schwartsburd, and N. C. Smith. 2002. Biochemical characterisation of the 56 and 82 kDa immunodominant gametocyte antigens from Eimeria maxima. Int. J. Parasitol. 32:805-816.
16. Belli, S. I., K. Mai, C. D. Skene, M. T. Gleeson, D. M. Witcombe, M. Katrib, A. Finger, M. G. Wallach, and N. C. Smith. 2004. Characterisation of the antigenic and immunogenic properties of bacterially expressed, sexual stage antigens of the coccidian parasite, Eimeria maxima. Vaccine 22:4316-4325.
17. Bergman, J. G., M. Muniz, D. Sutton, R. Fensome, F. Ling, and G. Paul. 2006. Comparative trial of the canine parvovirus, canine distemper virus and canine adenovirus type 2 fractions of two commercially available modified live vaccines. Vet. Rec. 159:733-736.
18. Bergman, P. J., J. McKnight, A. Novosad, S. Charney, J. Farrelly, D. Craft, M. Wulderk, Y. Jeffers, M. Sadelain, A. E. Hohenhaus, N. Segal, P. Gregor, M. Engelhorn, I. Riviere, A. N. Houghton, and J. D. Wolchok. 2003. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin. Cancer Res. 9:1284-1290.
19. Bethony, J. M., A. Loukas, P. J. Hotez, and D. P. Knox. 2006. Vaccines against blood-feeding nematodes of humans and livestock. Parasitology 133:S63-S79.
20. Blanchard, P., D. Mahe, R. Cariolet, A. Keranflec'h, M. A. Baudouard, P. Cordioli, E. Albina, and A. Jestin. 2003. Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins. Vaccine 21:4565-4575.
21. Borja-Cabrera, G. P., N. N. Correia Pontes, V. O. da Silva, E. Paraguai de Souza, W. R. Santos, E. M. Gomes, K. G. Luz, M. Palatnik, and C. B. Palatnik de Sousa. 2002. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20:3277-3284.
22. Borja-Cabrera, G. P., A. Cruz Mendes, E. Paraguai de Souza, L. Y. H. Okada, F. A. de A Trivellato, J. K. Kawasaki, A. C. Costa, A. B. Reis, O. Genaro, L. M. Batista, M. Palatnik, and C. B. Palatnik-de-Sousa. 2004. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22:2234-2243.
23. Boulter, N., and R. Hall. 1999. Immunity and vaccine development in the bovine theilerioses. Adv. Parasitol. 44:41-97.
24. Bouma, A. 2005. Determination of the effectiveness of Pseudorabies marker vaccines in experiments and field trials. Biologicals 33:241-245.
25. Bramwell, V. W., and Y. Perrie. 2006. Particulate delivery systems for vaccines: what can we expect? J. Pharm. Pharmacol. 58:717-728.
26. Brochier, B., M. P. Kieny, F. Costy, P. Coppens, B. Bauduin, J. P. Lecocq, B. Languet, G. Chappuis, P. Desmettre, K. Afiademanyo, et al. 1991. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 354:520-522.
27. Brown, R. G., W. D. Bowen, J. D. Eddington, W. C. Kimmins, M. Mezei, J. L. Parsons, and B. Pohajdak. 1997. Temporal trends in antibody production in captive grey, harp and hooded seals to a single administration immunocontraceptive vaccine. J. Reprod. Immunol. 35:53-64.
28. Bryans, J. T., E. R. Doll, J. C. Wilson, and W. H. McCollum. 1966. Immunization for equine influenza. J. Am. Vet. Med. Assoc. 148:413-417.
29. Bublot, M., N. Pritchard, D. E. Swayne, P. Selleck, K. Karaca, D. L. Suarez, J. C. Audonnet, and T. R. Mickle. 2006. Development and use of fowlpox vectored vaccines for avian influenza. Ann. N. Y. Acad. Sci. 1081:193-201.
30. Buxton, D., and E. A. Innes. 1995. A commercial vaccine for ovine toxoplasmosis. Parasitology 110:S11-S16.
31. Callow, L. L., R. J. Dalgliesh, and A. J. de Vos. 1997. Development of effective living vaccines against bovine babesiosis - the longest field trial? Int. J. Parasitol. 27:747-767.
32. Reference deleted.
33. Carter, P. B. 2003. The current state of veterinary vaccines: is there hope for the future? J. Vet. Med. Ed. 30:152-154.
34. Chalmers, W. S., J. Simpson, S. J. Lee, and W. Baxendale. 1997. Use of a live chlamydial vaccine to prevent ovine enzootic abortion. Vet. Rec. 141: 63-67.
35. Chiers, K., I. van Overbeke, P. De Laender, R. Ducatelle, S. Carel, and F. Haesebrouck. 1998. Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with inactivated vaccines containing the Apx toxins. Vet. Q. 20:65-69.
36. Clarke, I. J., H. M. Fraser, and A. S. McNeilly. 1978. Active immunization of ewes against luteinizing hormone releasing hormone, and its effects on ovulation and gonadotrophin, prolactin and ovarian steroid secretion. J. Endocrinol. 78:39-47.
37. Colombo, S., P. B. Hill, D. J. Shaw, and K. L. Thoday. 2005. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study. Vet. Dermatol. 16:162-170.
38. Cook, R. B., J. D. Popp, J. P. Kastelic, S. Robbins, and R. Harland. 2000. The effects of active immunization against gnRH on testicular development, feedlot performance, and carcass characteristics of beef bulls. J. Anim. Sci. 78:2778-2783.
39. Coquet, L., P. Cosette, L. Quillet, F. Petit, G. A. Junter, and T. Jouenne. 2002. Occurrence and phenotypic characterization of Yersinia ruckeri strains with biofilm-forming capacity in a rainbow trout farm. Appl. Environ. Microbiol. 68:470-475.
40. Cyranoski, D. 2005. Bird flu spreads among Java's pigs. Nature 435:390-391.
41. Dalgliesh, R. J., L. L. Callow, L. T. Mellors, and W. McGregor. 1981. Development of a highly infective Babesia bigemina vaccine of reduced virulence. Aust. Vet. J. 57:8-11.
42. Dantas-Torres, F. 2006. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet. Parasitol. 141:1-8.
43. Darteil, R., M. Bublot, E. Laplace, J. F. Bouquet, J. C. Audonnet, and M. Riviere. 1995. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology 211:481-490.
44. da Silva, V. O., G. P. Borja-Cabrera, N. N. Correia Pontes, E. P. de Souza, K. G. Luz, M. Palatnik, and C. B. Palatnik de Sousa. 2000. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 19:1082-1092.
45. Davis, B. S., G. J. Chang, B. Cropp, J. T. Roehrig, D. A. Martin, C. J. Mitchell, R. Bowen, and M. L. Bunning. 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75:4040-4047.
46. Day, M. J. 2006. Vaccine side effects: fact and fiction. Vet. Microbiol. 117:51-58.
47. Delves, P. J., T. Lund, and I. M. Roitt. 2002. Antifertility vaccines. Trends Immunol. 23:213-219.
48. de Waal, D. T., and M. P. Combrink. 2006. Live vaccines against bovine babesiosis. Vet. Parasitol. 138:88-96.
49. Doel, T. R. 2003. FMD vaccines. Virus Res. 91:81-99.
50. Dowsett, K. F., W. A. Pattie, L. M. Knott, A. E. Jackson, R. M. Hoskinson, R. P. Rigby, and B. A. Moss. 1991. A preliminary study of immunological castration in colts. J. Reprod. Fertil. Suppl. 44:183-190.
51. Dubey, J. P., and D. S. Lindsay. 1996. A review of Neospora caninum and neosporosis. Vet. Parasitol. 67:1-59.
52. Dufour, R., C. Roulet, C. Chouvet, and M. B. Bonneau. December 1996. Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals, vaccines which are usable in this method, new peptide, in particular, for producing these vaccines and vaccination kit relating thereto. U.S. patent 5573767.
53. Dunshea, F. R., C. Colantoni, K. Howard, I. McCauley, P. Jackson, K. A. Long, S. Lopaticki, E. A. Nugent, J. A. Simons, J. Walker, and D. P. Hennessy. 2001. Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases growth performance. J. Anim. Sci. 79:2524-2535.
54. Elhay, M., A. Newbold, A. Britton, P. Turley, K. Dowsett, and J. Walker. 2007. Suppression of behavioural and physiological oestrus in the mare by vaccination against GnRH. Aust. Vet. J. 85:35-45.
55. Fenaux, M., T. Opriessnig, P. G. Halbur, F. Elvinger, and X. J. Meng. 2004. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. J. Virol. 78:6297-6303.
56. Ferrari, M., A. Brack, M. G. Romanelli, T. C. Mettenleiter, A. Corradi, N. Dal Mas, M. N. Losio, R. Silini, C. Pinoni, and A. Pratelli. 2000. A study of the ability of a TK-negative and gI/gE-negative pseudorabies virus (PRV) mutant inoculated by different routes to protect pigs against PRV infection. J. Vet. Med. B Infect. Dis. Vet. Public Health 47:753-762.
57. Ferro, V. A., and W. H. Stimson. 1998. Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine. Vaccine 16:1095-1102.
58. Frey, J. 1995. Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol. 3:257-261.
59. Garcia de la Fuente, J. N., C. B. Gutierrez-Martin, N. Ortega, E. F. Rodriguez-Ferri, M. L. del Rio, O. R. Gonzalez, and J. Salinas. 2004. Efficacy of different commercial and new inactivated vaccines against ovine enzootic abortion. Vet. Microbiol. 100:65-76.
60. Reference deleted.
61. Gerdts, V., G. K. Mutwiri, S. K. Tikoo, and L. A. Babiuk. 2006. Mucosal delivery of vaccines in domestic animals. Vet. Res. 37:487-510.
62. Gerhardt, R. 2006. West Nile virus in the United States (1999-2005). J Am. Anim. Hosp. Assoc. 42:170-177.
63. Ghosh, S., J. Walker, and D. C. Jackson. 2001. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 104:58-66.
64. Gould, C. 2003. Successful oral vaccination. Skretting Outlook 20:10-11.
65. Graham, S. P., R. Pelle, Y. Honda, D. M. Mwangi, N. J. Tonukari, M. Yamage, E. J. Glew, E. P. de Villiers, T. Shah, R. Bishop, E. Abuya, E. Awino, J. Gachanja, A. E. Luyai, F. Mbwika, A. M. Muthiani, D. M. Ndegwa, M. Njahira, J. K. Nyanjui, F. O. Onono, J. Osaso, R. M. Saya, C. Wildmann, C. M. Fraser, I. Maudlin, M. J. Gardner, S. P. Morzaria, S. Loosmore, S. C. Gilbert, J. C. Audonnet, P. van der Bruggen, V. Nene, and E. L. Taracha. 2006. Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 103:3286-3291.
66. Grubman, M. J. 2005. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 33:227-234.
67. Guedes, R. M., and C. J. Gebhart. 2003. Onset and duration of fecal shedding, cell-mediated and humoral immune responses in pigs after challenge with a pathogenic isolate or attenuated vaccine strain of Lawsonia intracellularis. Vet. Microbiol. 91:135-145.
68. Reference deleted.
69. Haesebrouck, F., F. Pasmans, K. Chiers, D. Maes, R. Ducatelle, and A. Decostere. 2004. Efficacy of vaccines against bacterial diseases in swine: what can we expect? Vet. Microbiol. 100:255-268.
70. Hardham, J., K. Dreier, J. Wong, C. Sfintescu, and R. T. Evans. 2005. Pigmented-anaerobic bacteria associated with canine periodontitis. Vet. Microbiol. 106:119-128.
71. Hardham, J., M. Reed, J. Wong, K. King, B. Laurinat, C. Sfintescu, and R. T. Evans. 2005. Evaluation of a monovalent companion animal periodontal disease vaccine in an experimental mouse periodontitis model. Vaccine 23:3148-3156.
72. Hayes, E. B., and D. J. Gubler. 2006. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu. Rev. Med. 57:181-194.
73. Heppell, J., and H. L. Davis. 2000. Application of DNA vaccine technology to aquaculture. Adv. Drug Deliv. Rev. 43:29-43.
74. Reference deleted.
75. Hogge, G. S., J. K. Burkholder, J. Culp, M. R. Albertini, R. R. Dubielzig, N. S. Yang, and E. G. MacEwen. 1999. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther. 6:26-36.
76. Hoskinson, R. M., R. D. Rigby, P. E. Mattner, V. L. Huynh, M. D'Occhio, A. Neish, T. E. Trigg, B. A. Moss, M. J. Lindsey, G. D. Coleman, et al. 1990. Vaxstrate: an anti-reproductive vaccine for cattle. Aust. J. Biotechnol. 4:166-170, 176.
77. Huleatt, J. W., A. R. Jacobs, J. Tang, P. Desai, E. B. Kopp, Y. Huang, L. Song, V. Nakaar, and T. J. Powell. 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763-775.
78. Innes, E. A., S. Wright, P. Bartley, S. Maley, C. Macaldowie, I. Esteban-Redondo, and D. Buxton. 2005. The host-parasite relationship in bovine neosporosis. Vet. Immunol. Immunopathol. 108:29-36.
79. Jackwood, M. W., and Y. M. Saif. 1985. Efficacy of a commercial turkey coryza vaccine (Art-Vax) in turkey poults. Avian Dis. 29:1130-1139.
80. Jacobs, A. A., D. Goovaerts, P. J. Nuijten, R. P. Theelen, O. M. Hartford, and T. J. Foster. 2000. Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi. Vet. Rec. 147:563-567.
81. Jarosinski, K. W., B. K. Tischer, S. Trapp, and N. Osterrieder. 2006. Marek's disease virus: lytic replication, oncogenesis and control. Expert Rev. Vaccines 5:761-772.
82. Johnson, K. S., G. B. Harrison, M. W. Lightowlers, K. L. O'Hoy, W. G. Cougle, R. P. Dempster, S. B. Lawrence, J. G. Vinton, D. D. Heath, and M. D. Rickard. 1989. Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature 338:585-587.
83. Kahn, L. H. 2006. Confronting zoonoses, linking human and veterinary medicine. Emerg. Infect. Dis. 12:556-561.
84. Kelly, C., M. Bugg, C. Robinson, Z. Mitchell, N. Davis-Poynter, J. R. Newton, K. A. Jolley, M. C. Maiden, and A. S. Waller. 2006. Sequence variation of the SeM gene of Streptococcus equi allows discrimination of the source of strangles outbreaks. J. Clin. Microbiol. 44:480-486.
85. Kennedy, N. J., T. W. Spithill, J. Tennent, P. R. Wood, and D. Piedrafita. 2006. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. Vaccine 24:970-979.
86. Killian, G., L. Miller, J. Rhyan, and H. Doten. 2006. Immunocontraception of Florida feral swine with a single-dose GnRH vaccine. Am. J. Reprod. Immunol. 55:378-384.
87. Kirkbride, C. A. 1993. Diagnoses in 1,784 ovine abortions and stillbirths. J Vet. Diagn. Investig. 5:398-402.
88. Kocan, K. M., J. de la Fuente, A. A. Guglielmone, and R. D. Melendez. 2003. Antigens and alternatives for control of Anaplasma marginale infection in cattle. Clin. Microbiol. Rev. 16:698-712.
89. Kreeger, T. J., W. E. Cook, W. H. Edwards, P. H. Elzer, and S. C. Olsen. 2002. Brucella abortus strain RB51 vaccination in elk. II. Failure of high dosage to prevent abortion. J. Wildl. Dis. 38:27-31.
90. Kroll, J. J., M. B. Roof, and S. McOrist. 2004. Evaluation of protective immunity in pigs following oral administration of an avirulent live vaccine of Lawsonla intracellularis. Am. J. Vet. Res. 65:559-565.
91. Kuiken, T., G. Rimmelzwaan, D. van Riel, G. van Amerongen, M. Baars, R. Fouchier, and A. Osterhaus. 2004. Avian H5N1 influenza in cats. Science 306:241.
92. Ladd, A. E., C. Y. Wang, and T. J. Zamb. January 1998. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines. U.S. patent 5843446.
93. Lambert, P. H., M. Liu, and C. A. Siegrist. 2005. Can successful vaccines teach us how to induce efficient protective immune responses? Nat. Med. 11:S54-S62.
94. Larche, M., C. A. Akdis, and R. Valenta. 2006. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6:761-771.
95. Lea, I. A., E. E. Widgren, and M. G. O'Rand. 2002. Analysis of recombinant mouse zona pellucida protein 2 (ZP2) constructs for immunocontraception. Vaccine 20:1515-1523.
96. Lehman, J. R., R. M. Weigel, A. M. Siegel, L. G. Herr, A. C. Taft, and W. F. Hall. 1993. Progress after one year of a pseudorabies eradication program for large swine herds. J. Am. Vet. Med. Assoc. 203:118-121.
97. Liang, R., J. V. van den Hurk, L. A. Babiuk, and S. van Drunen Littel-van den Hurk. 2006. Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from bovine viral diarrhea virus in cattle. J. Gen. Virol. 87:2971-2982.
98. Lightowlers, M. W., and D. D. Heath. 2004. Immunity and vaccine control of Echinococcus granulosus infection in animal intermediate hosts. Parasitologia 46:27-31.
99. Lorenzen, N., and S. E. LaPatra. 2005. DNA vaccines for aquacultured fish. Rev. Sci. Tech. 24:201-213.
100. Mackowiak, M., J. Maki. L. Motes-Kreimeyer, T. Harbin, and K. Van Kampen. 1999. Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Adv. Vet. Med. 41:571-583.
101. Maes, R. K., M. D. Sussman, A. Vilnis, and B. J. Thacker. 1997. Recent developments in latency and recombination of Aujeszky's disease (pseudorabies) virus. Vet. Microbiol. 55:13-27.
102. Maizels, R. M., A. Balic, N. Gomez-Escobar, M. Nair, M. D. Taylor, and J. E. Allen. 2004. Helminth parasites - masters of regulation. Immunol. Rev. 201:89-116.
103. Marcelino, I., M. F. Sousa, C. Verissimo, A. E. Cunha, M. J. Carrondo, and P. M. Alves. 2006. Process development for the mass production of Ehrlichia ruminantium. Vaccine 24:1716-1725.
104. Marsh, A. E., J. Lakritz, P. J. Johnson, M. A. Miller, Y. W. Chiang, and H. J. Chu. 2004. Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine. Vet. Ther. 5:34-42.
105. Martens, A., A. De Moor, L. Vlaminck, F. Pille, and M. Steenhaut. 2001. Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids. Vet. Rec. 149:665-669.
106. McKeever, D. J., E. L. Taracha, W. I. Morrison, A. J. Musoke, and S. P. Morzaria. 1999. Protective immune mechanisms against Theileria parva: evolution of vaccine development strategies. Parasitol. Today 15:263-267.
107. McOrist, S., S. Jasni, R. A. Mackie, N. MacIntyre, N. Neef, and G. H. Lawson. 1993. Reproduction of porcine proliferative enteropathy with pure cultures of ileal symbiont intracellularis. Infect. Immun. 61:4286-4292.
108. Medina, E., and C. A. Guzman. 2001. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19:1573-1580.
109. Meeusen, E. N., and D. Piedrafita. 2003. Exploiting natural immunity to helminth parasites for the development of veterinary vaccines. Int. J. Parasitol. 33:1285-1290.
110. Reference deleted.
111. Reference deleted.
112. Miller, L. A., J. C. Rhyan, and M. Drew. 2004. Contraception of bison by GnRH vaccine: a possible means of decreasing transmission of brucellosis in bison. J. Wildl. Dis. 40:725-730.
113. Minke, J. M., J. C. Audonnet, and L. Fischer. 2004. Equine viral vaccines: the past, present and future. Vet. Res. 35:425-443.
114. Monath, T. P., J. Arroyo, C. Miller, and F. Guirakhoo. 2001. West Nile virus vaccine. Curr. Drug Targets Infect. Disord. 1:37-50.
115. Monath, T. P., J. Liu, N. Kanesa-Thasan, G. A. Myers, R. Nichols, A. Deary, K. McCarthy, C. Johnson, T. Ermak, S. Shin, J. Arroyo, F. Guirakhoo, J. S. Kennedy, F. A. Ennis, S. Green, and P. Bedford. 2006. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103:6694-6699.
116. Moormann, R. J., A. Bouma, J. A. Kramps, C. Terpstra, and H. J. De Smit. 2000. Development of a classical swine fever subunit marker vaccine and companion diagnostic test. Vet. Microbiol. 73:209-219.
117. Moreau, Y., E. Vidor, G. Bissuel, and N. Dubreuil. 1989. Vaccination against canine babesiosis: an overview of field observations. Trans. R. Soc. Trop. Med. Hyg. 83(Suppl):95-96.
118. Moriyon, I., M. J. Grillo, D. Monreal, D. Gonzalez, C. Marin, I. Lopez-Goni, R. C. Mainar-Jaime, E. Moreno, and J. M. Blasco. 2004. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet. Res. 35:1-38.
119. Morrow, C. J., J. F. Markham, and K. G. Whithear. 1998. Production of temperature-sensitive clones of Mycoplasma synoviae for evaluation as live vaccines. Avian Dis. 42:667-670.
120. Mortensen, S., R. Stryhn, A. Boklund, K. D. Stark, J. Christensen, and P. Willeberg. 2002. Risk factors for infection of sow herds with porcine reproductive and respiratory syndrome (PRRS) virus. Prev. Vet. Med. 53:83-101.
121. Murphy, F. A., E. P. J. Gibbs, M. C. Horzinek, and M. J. Studdert. 1999. Veterinary virology, 3rd ed. Academic Press, London, United Kingdom.
122. Murtaugh, M. P., M. R. Elam, and L. T. Kakach. 1995. Comparison of the structural protein coding sequences of the VR-2332 and Lelystad virus strains of the PRRS virus. Arch. Virol. 140:1451-1460.
123. Newton, S. E., and E. N. Meeusen. 2003. Progress and new technologies for developing vaccines against gastrointestinal nematode parasites of sheep. Parasite Immunol. 25:283-296.
124. Nielsen, K., D. R. Ewalt, B. Garin-Bastuji, A. P. MacMillan, J. Stack, and P. Wright. 2004. Bovine brucellosis, p. 409-438. In Office International des Epizooties (ed.), Manual of diagnostic tests and vaccines for terrestrial animals. Office International des Epizooties, Paris, France.
125. Nogueira, F. S., M. A. Moreira, G. P. Borja-Cabrera, F. N. Santos, I. Menz, L. E. Parra, Z. Xu, H. J. Chu, C. B. Palatnik-de-Sousa, and M. C. Luvizotto. 2005. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23:4805-4810.
126. Nuttall, P. A., A. R. Trimnell, M. Kazimirova, and M. Labuda. 2006. Exposed and concealed antigens as vaccine targets for controlling ticks and tick-borne diseases. Parasite Immunol. 28:155-163.
127. O'Hern, P. A., C. S. Bambra, M. Isahakia, and E. Goldberg. 1995. Reversible contraception in female baboons immunized with a synthetic epitope of sperm-specific lactate dehydrogenase. Biol. Reprod. 52:331-339.
128. Olson, M. E., H. Ceri, and D. W. Morck. 2000. Giardia vaccination. Parasitol. Today 16:213-217.
129. Olson, M. E., D. W. Morck, and H. Ceri. 1997. Preliminary data on the efficacy of a Giardia vaccine in puppies. Can. Vet. J. 38:777-779.
130. Paillot, R., D. Hannant, J. H. Kydd, and J. M. Daly. 2006. Vaccination against equine influenza: quid novi? Vaccine 24:4047-4061.
131. Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. USA 93:11349-11353.
132. Pardo, M. C., and M. Mackowiak. 1999. Efficacy of a new canine-origin, modified-live virus vaccine against canine coronavirus. Canine Practice 24:6-8.
133. Park, M. S., J. Steel, A. Garcia-Sastre, D. Swayne, and P. Palese. 2006. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. USA 103:8203- 8208.
134. Pashine, A., N. M. Valiante, and J. B. Ulmer. 2005. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:S63-S68.
135. Pastoret, P. P., and B. Brochier. 1999. Epidemiology and control of fox rabies in Europe. Vaccine 17:1750-1754.
136. Pastoret, P. P., and P. Jones. 2004. Veterinary vaccines for animal and public health. Dev. Biol. (Basel) 119:15-29.
137. Pensaert, M., G. Labarque, H. Favoreel, and H. Nauwynck. 2004. Aujeszky's disease vaccination and differentiation of vaccinated from infected pigs. Dev. Biol. (Basel) 119:243-254.
138. Perrin, B., M. Perrin, A. Moussa, and M. Coudert. 1996. Evaluation of a commercial gE blocking ELISA test for detection of antibodies to infectious bovine rhinotracheitis virus. Vet. Rec. 138:520.
139. Philippon, V. 2006. Modified vaccinia Ankara (MVA) vector vaccines. University of California San Francisco School of Medicine, San Francisco, CA. http://chi.ucsf.edu/vaccines/vaccines?page=vc-01-04.
140. Pipano, E., and V. Shkap. 2000. Vaccination against tropical theileriosis. Ann. N. Y. Acad. Sci. 916:484-500.
141. Plowright, W. 1972. The production and use of rinderpest cell culture vaccine in developing countries. World Anim. Rev. 1:14-18.
142. Pluimers, F. H. 2004. Foot-and-mouth disease control using vaccination: the Dutch experience in 2001. Dev. Biol. (Basel) 119:41-49.
143. Powell, K. 2004. DNA vaccines - back in the saddle again? Nat. Biotechnol. 22:799-801.
144. Pulendran, B., and R. Ahmed. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124: 849-863.
145. Rank, R. G. 1999. Models of immunity, p. 239-295. In R. S. Stephens (ed.), Chlamydia: intracellular biology, pathogenesis, and immunity. American Society for Microbiology, Washington, DC.
146. Rautenschlein, S., C. Kraemer, J. Vanmarcke, and E. Montiel. 2005. Protective efficacy of intermediate and intermediate plus infectious bursal disease virus (IBDV) vaccines against very virulent IBDV in commercial broilers. Avian Dis. 49:231-237.
147. Robbins, S. C., M. D. Jelinski, and R. L. Stotish. 2004. Assessment of the immunological and biological efficacy of two different doses of a recombinant GnRH vaccine in domestic male and female cate (Felis catus). J. Reprod. Immunol. 64:107-119.
148. Rodolakis, A. 1983. In vitro and in vivo properties of chemically induced temperature-sensitive mutants of Chlamydia psittaci var. ovis: screening in a murine model. Infect. Immun. 42:525-530.
149. Rodolakis, A., and A. Souriau. 1986. Response of goats to vaccination with temperature-sensitive mutants of Chlamydia psittaci obtained by nitrosoguanidine mutagenesis. Am. J. Vet. Res. 47:2627-2631.
150. Roeder, P. 2006. Rinderpest eradication - is it feasible? p. 61-62. In I. Olsen and T. Gjøen (ed.), Proceedings of the International Veterinary Vaccine and Diagnostics Conference, Oslo, Norway. Reprosentralen, University of Oslo, Oslo, Norway.
151. Romero, J. J., E. Perez, and K. Frankena. 2004. Effect of a killed whole Neospora caninum tachyzoite vaccine on the crude abortion rate of Costa Rican dairy cows under field conditions. Vet. Parasitol. 123:149-159.
152. Rupprecht, C. E., C. A. Hanlon, and D. Slate. 2004. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev. Biol. (Basel) 119:173-184.
153. Rutten, V. P., W. R. Klein, W. A. De Jong, W. Misdorp, P. A. Steerenberg, W. H. De Jong, W. Den Otter, and E. J. Ruitenberg. 1991. Immunotherapy of bovine ocular squamous cell carcinoma by repeated intralesional injections of live bacillus Calmette-Guerin (BCG) or BCG cell walls. Cancer Immunol. Immunother. 34:186-190.
154. Scheerlinck, J. P., and D. L. Greenwood. 2006. Particulate delivery systems for animal vaccines. Methods 40:118-124.
155. Scheerlinck, J. P., J. Karlis, T. E. Tjelle, P. J. Presidente, I. Mathiesen, and S. E. Newton. 2004. In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 22:1820-1825.
156. Schetters, T. 2005. Vaccination against canine babesiosis. Trends Parasitol. 21:179-184.
157. Schurig, G. G., R. M. Roop II, T. Bagchi, S. Boyle, D. Buhrman, and N. Sriranganathan. 1991. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet. Microbiol. 28:171-188.
158. Schurig, G. G., N. Sriranganathan, and M. J. Corbel. 2002. Brucellosis vaccines: past, present and future. Vet. Microbiol. 90:479-496.
159. Schynts, F., E. Baranowski, M. Lemaire, and E. Thiry. 1999. A specific PCR to differentiate between gE negative vaccine and wildtype bovine herpesvirus type 1 strains. Vet. Microbiol. 66:187-195.
160. Sedgmen, B. J., S. A. Lofthouse, and E. N. Meeusen. 2006. The ovine nasal mucosa: an alternative tissue site for mucosal immunization. Methods 38: 112-116.
161. Seregin, A., R. Nistler, V. Borisevich, G. Yamshchikov, E. Chaporgina, C. W. Kwok, and V. Yamshchikov. 2006. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives. Virology 356:115-125.
162. Seya, T., T. Akazawa, J. Uehori, M. Matsumoto, I. Azuma, and K. Toyoshima. 2003. Role of Toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 23:4369-4376.
163. Shams, H. 2005. Recent developments in veterinary vaccinology. Vet. J. 170:289-299.
164. Shirley, M. W., A. L. Smith, and F. M. Tomley. 2005. The biology of avian Eimeria with an emphasis on their control by vaccination. Adv. Parasitol. 60:285-330.
165. Shkap, V., and E. Pipano. 2000. Culture-derived parasites in vaccination of cattle against tick-borne diseases. Ann. N. Y. Acad. Sci. 916:154-171.
166. Shryock, T. R. 2004. The future of anti-infective products in animal health. Nat. Rev. Microbiol. 2:425-430.
167. Simard, N., C. Lyngoy, V. Funk, G. Traxler, S. LaPatra, and K. Salonius. 2006. Research to market: meeting safety and efficacy requirements for a DNA vaccine used in Atlantic salmon, p. 46. In I. Olsen and T. Gjøen (ed.), Proceedings of the International Veterinary Vaccine and Diagnostics Conference, Oslo, Norway. Reprosentralen, University of Oslo, Oslo, Norway.
168. Simms, M. S., D. P. Scholfield, E. Jacobs, D. Michaeli, P. Broome, J. E. Humphreys, and M. C. Bishop. 2000. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br. J. Cancer 83:443-446.
169. Singh, M., and D. T. O'Hagan. 2003. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 33:469-478.
170. Slate, D., C. E. Rupprecht, J. A. Rooney, D. Donovan, D. H. Lein, and R. B. Chipman. 2005. Status of oral rabies vaccination in wild carnivores in the United States. Virus Res. 111:68-76.
171. Stevens, V. C. 1997. Some reproductive studies in the baboon. Hum. Reprod. Update 3:533-540.
172. Stoffregen, W. C., S. C. Olsen, and B. J. Bricker. 2006. Parenteral vaccination of domestic pigs with Brucella abortus strain RB51. Am. J. Vet. Res. 67:1802-1808.
173. Stout, T. A., and B. Colenbrander. 2004. Suppressing reproductive activity in horses using GnRH vaccines, antagonists or agonists. Anim. Reprod. Sci. 82-83:633-643.
174. Sweeney, C. R., J. F. Timoney, J. R. Newton, and M. T. Hines. 2005. Streptococcus equi infections in horses: guidelines for treatment, control, and prevention of strangles. J. Vet. Intern. Med. 19:123-134.
175. Taylor, G. 2000. Castration - an abbreviated history of western manhood. Routledge, New York, NY.
176. Taylor, J., B. Meignier, J. Tartaglia, B. Languet, J. VanderHoeven, G. Franchini, C. Trimarchi, and E. Paoletti. 1995. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13:539-549.
177. Timoney, J. F., and D. Eggers. 1985. Serum bactericidal responses to Streptococcus equi of horses following infection or vaccination. Equine Vet. J. 17:306-310.
178. Tshewang, U., K. F. Dowsett, L. M. Knott, and T. E. Trigg. 1997. Preliminary study of ovarian activity in fillies treated with a GnRH vaccine. Aust. Vet. J. 75:663-667.
179. Tung, K. S., P. Primakoff, L. Woolman-Gamer, and D. G. Myles. 1997. Mechanism of infertility in male guinea pigs immunized with sperm PH-20. Biol. Reprod. 56:1133-1141.
180. Umetsu, D. T., and R. H. DeKruyff. 2006. The regulation of allergy and asthma. Immunol. Rev. 212:238-255.
181. van Aarle, P. 2003. Suitability of an E2 subunit vaccine of classical swine fever in combination with the E(rns)-marker-test for eradication through vaccination. Dev. Biol. (Basel) 114:193-200.
182. van den Bosch, H., and J. Frey. 2003. Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs. Vaccine 21:3601-3607.
183. van Drunen Littel-van den Hurk, S., S. Babiuk, and L. A. Babiuk. 2006. Needle-free delivery of veterinary DNA vaccines. Methods Mol. Med. 127: 91-105.
184. Van Immerseel, F., U. Methner, I. Rychlik, B. Nagy, P. Velge, G. Martin, N. Foster, R. Ducatelle, and P. A. Barrow. 2005. Vaccination and early protection against non-host-specific Salmonella serotypes in poultry: exploitation of innate immunity and microbial activity. Epidemiol. Infect. 133:959-978.
185. van Oirschot, J. T., M. J. Kaashoek, and F. A. Rijsewijk. 1996. Advances in the development and evaluation of bovine herpesvirus 1 vaccines. Vet. Microbiol. 53:43-54.
186. Van Overbeke, I., K. Chiers, R. Ducatelle, and F. Haesebrouck. 2001. Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins. J. Vet. Med. B Infect. Dis. Vet. Public Health 48:15-20.
187. Veits, J., D. Wiesner, W. Fuchs, B. Hoffmann, H. Granzow, E. Starick, E. Mundt, H. Schirrmeier, T. Mebatsion, T. C. Mettenleiter, and A. Romer-Oberdorfer. 2006. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. USA 103:8197-8202.
188. Vemulapalli, R., J. R. McQuiston, G. G. Schurig, N. Sriranganathan, S. M. Halling, and S. M. Boyle. 1999. Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains. Clin. Diagn. Lab. Immunol. 6:760-764.
189. Vercruysse, J., D. P. Knox, T. P. Schetters, and P. Willadsen. 2004. Veterinary parasitic vaccines: pitfalls and future directions. Trends Parasitol. 20:488-492.
190. Vretou, E., E. Psarrou, M. Kaisar, I. Vlisidou, V. Salti-Montesanto, and D. Longbottom. 2001. Identification of protective epitopes by sequencing of the major outer membrane protein gene of a variant strain of Chlamydia psittaci serotype 1 (Chlamydophila abortus). Infect. Immun. 69:607-612.
191. Walker, J. A., and J. F. Timoney. 2002. Construction of a stable non-mucoid deletion mutant of the Streptococcus equi Pinnacle vaccine strain. Vet. Microbiol. 89:311-321.
192. Wallach, M. 1997. The importance of transmission-blocking immunity in the control of infections by apicomplexan parasites. Int. J. Parasitol. 27: 1159-1167.
193. Wallach, M., N. C. Smith, M. Petracca, C. M. Miller, J. Eckert, and R. Braun. 1995. Eimeria maxima gametoeyte antigens: potential use in a subunit maternal vaccine against coceidiosis in chickens. Vaccine 13:347-354.
194. Whetstone, C. A., J. M. Miller, B. S. Seal, L. J. Bello, and W. C. Lawrence. 1992. Latency and reactivation of a thymidine kinase-negative bovine herpesvirus 1 deletion mutant. Arch. Virol. 122:207-214.
195. Willadsen, P. 2004. Anti-tick vaccines. Parasitology 129:S367-S387.
196. Williams, R. B. 2002. Fifty years of anticoccidial vaccines for poultry (1952-2002). Avian Dis. 46:775-802.
197. Yen, H. H., J. P. Scheerlinck, S. Gekas, and P. Sutton. 2006. A sheep cannulation model for evaluation of nasal vaccine delivery. Methods 38: 117-123.
198. Zweygarth, E., A. I. Josemans, M. F. Van Strijp, L. Lopez-Rebollar, M. Van Kleef, and B. A. Allsopp. 2005. An attenuated Ehrlichia ruminantium (Welgevonden stock) vaccine protects small ruminants against virulent heartwater challenge. Vaccine 23:1695-1702.